Stockscreener 앱 받기
10.54
18.04%
-2.32
시장 영업 전:
11.93
1.39
+13.19%
전일 마감가:
$12.86
열려 있는:
$13.25
하루 거래량:
60,775
Relative Volume:
0.59
시가총액:
$219.56M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+4.15%
1개월 성능:
+29.17%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$10.42
$13.25
1주일 범위
$9.36
$13.56
52주 변동 폭
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
명칭
Aardvark Therapeutics Inc
전화
(858) 225-7696
주소
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
AARD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
10.54 | 219.56M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-10 | 개시 | BofA Securities | Buy |
| 2025-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-10 | 개시 | Morgan Stanley | Overweight |
| 2025-03-10 | 개시 | RBC Capital Mkts | Outperform |
Aardvark Therapeutics Inc 주식(AARD)의 최신 뉴스
Aardvark Therapeutics Inc’s Market Journey: Closing Strong at 7.79, Up 6.86 - DWinneX
Aardvark Therapeutics (NASDAQ:AARD) Trading Up 7.6% – What’s Next? - Defense World
Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings - insights.citeline.com
Aardvark Therapeutics (NASDAQ:AARD) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock - Investing.com Australia
RBC Capital maintains $21 target on Aardvark Therapeutics stock - Investing.com Australia
RBC Capital maintains $21 target on Aardvark Therapeutics stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock By Investing.com - Investing.com South Africa
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times
Aardvark Therapeutics Inc. (AARD) reports earnings - qz.com
Bank of America Boosts Aardvark Therapeutics (NASDAQ:AARD) Price Target to $26.00 - Defense World
BofA lifts Aardvark Therapeutics target to $26, maintains Buy By Investing.com - Investing.com Canada
Positive Outlook for Aardvark Therapeutics Amid Favorable Regulatory and Market Conditions - TipRanks
BofA lifts Aardvark Therapeutics target to $26, maintains Buy - Investing.com Australia
Aardvark Therapeutics price target raised to $26 from $22 at BofA - TipRanks
Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (NASDAQ:SLNO) - Seeking Alpha
Aardvark Therapeutics, Inc.’s Quiet Period Will End on March 25th (NASDAQ:AARD) - Defense World
Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month - Insider Monkey
Top 10 Insider Purchases Last Month - Insider Monkey
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Royal Bank of Canada - Defense World
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Morgan Stanley - Defense World
BofA sets Aardvark Therapeutics stock with $22 target By Investing.com - Investing.com Australia
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Analysts at Cantor Fitzgerald - Defense World
BofA Initiates Aardvark Therapeutics at Buy With $22 Price Target -March 10, 2025 at 10:01 am EDT - Marketscreener.com
RBC Capital sets Aardvark Therapeutics at Outperform - Investing.com
This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
RBC Capital sets Aardvark Therapeutics at Outperform By Investing.com - Investing.com South Africa
Aardvark Therapeutics initiated with an Overweight at Cantor Fitzgerald - TipRanks
Morgan Stanley Initiates Aardvark Therapeutics at Overweight -March 10, 2025 at 08:13 am EDT - Marketscreener.com
Cantor Fitzgerald Initiates Aardvark Therapeutics at Overweight With $50 Price Target -March 10, 2025 at 08:03 am EDT - Marketscreener.com
BofA sets Aardvark Therapeutics stock with $22 target - Investing.com India
RBC Initiates Aardvark Therapeutics at Outperform With $21 Price Target, Speculative Risk Qualifier - Marketscreener.com
Morgan Stanley sets Aardvark stock target at $29, rating Overweight By Investing.com - Investing.com South Africa
Morgan Stanley sets Aardvark stock target at $29, rating Overweight - Investing.com
San Diego had its first biotech IPO of 2025. Are more on the way? - MSN
Aardvark Therapeutics’ $94.2 Million Initial Public Offering - Global Legal Chronicle
Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip
Biotechs Highlight 6 Stocks Insiders Are Buying Now - 24/7 Wall St.
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.
Big Moves: Major Stakeholders Invest Heavily in Aardvark Therapeutics - TipRanks
Autism Spectrum Disorder Treatment Market Size is expected - openPR
Aardvark therapeutics sees $20m stock purchase by Decheng capital - Investing.com India
Aardvark Therapeutics Inc (AARD) 재무 분석
Aardvark Therapeutics Inc (AARD)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Aardvark Therapeutics Inc 주식 (AARD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lee Tien-Li | Chief Executive Officer |
Feb 14 '25 |
Buy |
16.00 |
16,542 |
264,672 |
1,496,175 |
| Sun Nelson | Chief Financial Officer |
Feb 14 '25 |
Buy |
16.00 |
10,000 |
160,000 |
99,484 |
| Cormorant Asset Management, LP | Former 10% Owner |
Feb 14 '25 |
Buy |
16.00 |
187,500 |
3,000,000 |
987,689 |
0.39%
3.66%
자본화:
|
볼륨(24시간):